Bayer HealthCare / Press

Bayer HealthCare initiates discussion regarding public awareness of benefits and risks of modern contraception

Bayer HealthCare has invited international experts to debate approaches how to increase awareness on the benefits and potential risks of modern contraception. This topic was recently subject to a number of controversial media reports and European regulatory actions. more      

In Focus

Healthcare News

  • 2014-04-09 Bayer HealthCare initiates discussion regarding public awareness of benefits and risks of modern contraception
    2014-04-09

    Bayer HealthCare initiates discussion regarding public awareness of benefits and risks of modern contraception

    Today, various contraceptive methods offer solutions tailored to women’s needs and their individual life situations. While it is clear that modern contraception is the primary method for family planning and prevention of unintended pregnancy, reoccurring discussions on the benefit/risk profile of combined hormonal contraceptives among healthcare experts as well as in the public could lead to uncertainty for women regarding which method individually is the right one for them. more

  • 2014-04-04 Bayer to Present New Data on Advancing Oncology Portfolio
    2014-04-04

    Bayer to Present New Data on Advancing Oncology Portfolio

    Bayer HealthCare (Bayer) will present latest preclinical and clinical data on promising early-stage compounds with new mechanism of action at the American Association for Cancer Research (AACR) 105th Annual Meeting, April 5-9, 2014, in San Diego, CA. more

  • 2014-04-02 Bayer Initiates Phase III Trial of Radium-223 Dichloride in Combination with Abiraterone Acetate for Patients with Metastatic Castration-Resistant Prostate Cancer
    2014-04-02

    Bayer Initiates Phase III Trial of Radium-223 Dichloride in Combination with Abiraterone Acetate for Patients with Metastatic Castration-Resistant Prostate Cancer

    Bayer HealthCare today announced that the company has begun to enroll patients in a new Phase III trial with radium-223 dichloride (radium-223, Xofigo®). The study evaluates radium-223 in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer (CRPC). more

Photos & Videos

  • Photos

    Photo galleries with topic-related images.
    more

  • TV Footage

    In this section you can find videos for editorial coverage.
    more

Bayer HealthCare Links


http://press.healthcare.bayer.com/en/press/index.php

Copyright © Bayer HealthCare AG